Drug Profile
Tasurgratinib succinate - Eisai
Alternative Names: E-7090Latest Information Update: 08 Feb 2024
Price :
$50
*
At a glance
- Originator Eisai Co Ltd
- Class Amides; Amines; Antineoplastics; Benzene derivatives; Ethers; Indoles; Piperidines; Pyridines; Small molecules
- Mechanism of Action Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Biliary cancer
- Phase II Cholangiocarcinoma; Solid tumours
- Phase I Breast cancer
Most Recent Events
- 22 Jan 2024 Phase-I development in Breast-cancer (Combination therapy, Monotherapy, Metastatic disease, Recurrent) is still ongoing in Japan (PO, Tablet) (NCT04572295)
- 18 Jan 2024 Efficacy and adverse events data from a phase II trial in Cholangiocarcinoma presented at the 2024 Gastrointestinal Cancers Symposium (ASCO-GCS-2024)
- 18 Dec 2023 Preregistration for Biliary cancer in Japan (PO) (biliary tract cancer with FGFR2 gene fusion)